epiXchange conference

23 May 2018, Brussels

Seven large EC-funded projects on epilepsy co-organise this conference to disseminate project results and discuss the future of epilepsy research in the EU and worldwide.


DESIRE focuses on epileptogenic developmental disorders EDD, i.e. early onset epilepsies whose origin is closely related to developmental brain processes. The project studies genetic and epigenetic factors and develops novel diagnostics and treatment strategies.

To project »


EpiCARE is a European Reference Network focusing on rare and complex epilepsies. EpiCARE aims to develop and deliver highly-specialised diagnostics and care to improve interventions and outcome in individuals with rare and complex epilepsies.

To project »


Focuses on molecules called microRNAs (miRNAs). Its goals have been to discover which miRNAs are altered in models of epilepsy and patients, determine how this contributes to epilepsy, look for possible genetic variation in miRNAs in patients and explore the potential of miRNA-based treatments.

To project »


EpiPGX aimed to identify genome-based biomarkers for use in clinical practice to individualise treatment of epilepsy, and stratify patients for clinical trials, aiming to avoid chronicity, prevent relapse and reduce adverse drug reactions (ADRs). The project ended in 2015.

To project »


The aim of EPISTOP is to better understand the pathophysiology of epilepsy and its consequences, to develop a preventative strategy for epilepsy, to identify new biomarkers of epilepsy, and to develop new therapeutic targets to block or otherwise modify epileptogenesis in humans.

To project »


EPITARGET is focused on the process leading to epilepsy (epileptogenesis) in adults. The project studies biomarkers and multiple basic mechanisms for epileptogenesis and translate these findings to the clinic by validating the biomarkers in human samples.

To project »


The main objective of the “Innovative gene therapies for epilepsy treatment” (Epixchange) project was to explore, provide the bases for clinical application and implement in the industrial arena new, advanced, unconventional strategies for the therapy of partial epilepsies. The project ended in 2015.

To project »